Compositions for use in the prevention or treatment of URT infections in infants or young children at risk
A composition contains at least one fucosylated oligosaccharide, for use in preventing and/or treating a URT infection in an infant or young child fulfilling at least one of the following criteria: i) the infant or young child is born from a non-secretor mother and/or is fed with a mother's milk deficient in at least one fucosylated oligosaccharide, ii) the infant or young child has at least one sibling, and iii) the infant or young child was born by C-section.
1. A method for preventing and/or treating an upper respiratory tract (URT) infection in an infant or young child, the method comprising administering a composition comprising 0.5 g/L to 5 g/L of 2′-fucosyllactose to an infant or young child,
wherein the infant or young child is fed with a mother's milk deficient in at least one fucosylated oligosaccharide, and the infant or young child has at least one sibling.
2. The method according to claim 1 wherein the composition further comprises at least one additional fucosylated oligosaccharide selected from the group consisting of 3′fucosyllactose, difucosyllactose, lacto-N-fucopentaose I, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N-fucohexaose, lacto-N-difucohexaose I, fucosyllacto-N-hexaose, fucosyllacto-N-neohexaose I, fucosyllacto-N-neohexaose II, difucosyllacto-N-hexaose I, difucosyllacto-N-neohexaose I, difucosyllacto-N-neohexaose II, fucosyl-para-Lacto-N-hexaose, and combinations thereof.
3. The method according to claim 1 wherein the composition is administered to the infant during at least the first week after birth.
4. The method according to claim 1 wherein the 2′-fucosyllactose is the only human milk oligosaccharide in the composition, and the composition does not contain any carotenoid.
5. The method according to claim 1 wherein the 2′-fucosyllactose is 1 g/L to 4.5 g/L of the composition.
6. The method according to claim 1 comprising administering at least another human milk oligosaccharide and/or precursor thereof to the infant or young child.
7. The method according to claim 6 wherein the at least one human milk oligosaccharide and/or precursor thereof is selected from the group consisting of N-acetylated oligosaccharide, sialylated oligosaccharide, sialic acid, fucose and combinations thereof.
8. The method according to claim 7 , wherein the N-acetylated oligosaccharide is selected from the group consisting of lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT) and combinations thereof.
9. The method according to claim 7 , wherein the sialylated oligosaccharide is selected from the group consisting of 3′ sialyllactose (3-SL), 6′ sialyllactose (6-SL), and combinations thereof.
10. The method according to claim 1 comprising administering to the infant or young child at least another human milk oligosaccharide and/or precursor thereof selected from the group consisting of lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 3′ sialyllactose (3-SL), 6′ sialyllactose (6-SL), sialic acid and combinations thereof.
11. The method according to claim 1 , wherein the composition further comprises at least one probiotic in an amount of from 10 3 to 10 12 cfu/g of said composition (dry weight).
12. The method according to claim 1 , wherein the composition is selected from the group consisting of a nutritional composition, a preparation and a food product.
13. The method according to claim 1 , wherein the composition is selected from the group consisting of an infant formula, a starter infant formula, a follow-on infant formula, a baby food, an infant cereal composition, a fortifier and a supplement.
14. The method according to claim 1 , wherein the infant or young child is preterm.
15. The method according to claim 1 , wherein the infant or young child is a secretor.
16. The method according to claim 1 , wherein the composition has a LNT:LNnT weight ratio from 2:1 to 1:1, and/or the infant or young child was born by C-section.